Latest in News & Research
Smoking Cessation Linked to Lower Risk for Hidradenitis Suppurativa
HS risk lower for smoking quitters, those who maintained cessation status, and never smokers versus sustained smokers
LAUNCH ALERT: Positive Results Released from LEVEL UP Trial Comparing Upadacitinib and Dupilumab for Atopic Dermatitis
Upadacitinib outperforms dupilumab in achieving superior efficacy for atopic dermatitis
Skin of Color Has More Adverse Events From Sclerotherapy
Postinflammatory hyperpigmentation seen more often versus lighter skin tones
LAUNCH ALERT: Nemluvio Gains FDA Approval for Prurigo Nodularis
Galderma’s nemolizumab is the first monoclonal antibody to specifically target IL-31 signaling
FDA Approves Nemluvio for Prurigo Nodularis
Clinical trials show significant benefits for itch, skin nodules, and sleep disturbance versus placebo
Survival Plateaus After Three Years of ICI Treatment of Advanced Melanoma
Findings show decrease in survival from three years of treatment to five years for patients treated with ICIs in clinical practice
Withdrawal of Baricitinib Results in Loss of Benefit in Severe Alopecia
80 percent of patients with withdrawal of treatment lose benefit; most recapture benefit after retreatment
Gene Expression Signature Predicts Immune-Related Adverse Events in Melanoma Patients
Gene expression signature predicts irAEs in melanoma patients treated with ipilimumab/nivolumab
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
23.8 percent of patients discontinued dupilumab, with adverse events and ineffectiveness the most common reasons
Racial Differences Identified in Frequency of Biopsy for Psoriasis
Skin biopsies, indicating diagnostic uncertainty, performed most frequently for Black patients
Extending Dosing Interval for Guselkumab Noninferior in Psoriasis
Extending the interval to 16 weeks from eight weeks is noninferior for patients with moderate-to-severe psoriasis
Clear Margins Seen for 89.2 Percent After Initial Excision of Lentigo Maligna
Seven patients received more than one excision; one of these tumors was recurrent lentigo maligna
Alopecia Tied to Higher Prevalence of Autoimmune, Psychiatric Comorbidities
Higher risk for incident comorbidities also seen compared with matched controls without alopecia
FDA Approves Leqselvi for Severe Alopecia
JAK inhibitor associated with significant improvements in scalp hair coverage at 24 weeks
LAUNCH ALERT: FDA Approves Deuruxolitinib (LEQSELVI) for Severe Alopecia Areata
The twice-daily, oral, selective JAK 1 and 2 inhibitor is the third systemic medication approved for severe alopecia areata in adults
FDA Warns Against Using Chemical Peels Without Professional Supervision
People who are buying and using at-home chemical peels are ending up burned and scarred
Relatively High Frequency of Emergency Complications Seen for Dermatological Procedures
53 percent of dermatologists reported emergency complications during dermatological and surgical procedures; 43.2 percent during cosmetic procedures
Serum Zinc, Selenium, Vitamin D Levels Lower in Acne Vulgaris Patients
Levels also lower in patients with grade 4 acne compared with other disease severity grades
Site-Specific Melanoma Trends May Be Related to Genetic Risk
Association between polygenic risk score and melanoma of the trunk differs between men and women
Gen Z Perceives Atopic Dermatitis to Be More Severe
Perceived severity higher among Gen Z compared with millennial patients
Atopic Dermatitis Has Large Impact on Sexual Function Among Women
About half of women considered that atopic dermatitis may influence their gestational desire
Psoriasis, Psoriatic Arthritis Tied to Higher Risk of Polyneuropathy
However, increased risk seems to be linked to the higher prevalence of contributing factors for polyneuropathy
Hydroxychloroquine Safe, Effective Treatment for Anogenital Lichen Sclerosus
Response rate higher for anogenital versus extragenital lichen sclerosus
24 of 1200